Condition
Sarcomas
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownAerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesNCT04648826 · 2021-12-14
WITHDRAWNSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNCT04140526 · 2020-09-16
ACTIVE_NOT_RECRUITINGBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)NCT02568267 · 2015-11-19
ACTIVE_NOT_RECRUITINGDendritic Cell Vaccination for Patients with Solid TumorsNCT01291420 · 2010-05-03
COMPLETEDOpen Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple MyelomaNCT00847366 · 2008-05-01
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING2
COMPLETED2
WITHDRAWN1
Phase mix
PHASE24
PHASE13
NA1
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.